TAK
NYSETakeda Pharmaceutical Company Limited
Price$16.53-0.02 (-0.12%)
01:30 PM07:45 PM
News · 26 weeks67-64%
2025-11-092026-05-03
Mix5190d
- Insider37(73%)
- Other6(12%)
- SEC Filings5(10%)
- Leadership1(2%)
- Earnings1(2%)
- Analyst1(2%)
Latest news
25 items- PRBritish Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel SyndromeTORONTO, May 5, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") announced that REVESTIVE® (teduglutide for injection) will now be reimbursed by BC PharmaCare for eligible pediatric and adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.1 Coverage is subject to specific criteria.2 For people living with SBS, reimbursed access can help reduce reliance on parenteral support, which includes intravenous administration of nutrition, fluids, and electrolytes."We welcome the Government of B.C.'s decision to reimburse REVESTIVE for people living with Short
- INSIDERSEC Form 3 filed by new insider Smoter Jennifer Marie3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- PRTakeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda ((TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrate
- INSIDERPresident and CEO Weber Christophe Pierre was granted 78,900 units of Ordinary Shares and was granted 165,370 units of American Depositary Shares, decreasing direct ownership by 55% to 418,803 units (SEC Form 4) to cover taxes4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, R&D Plump Andrew Stewart was granted 212,470 units of American Depositary Shares, increasing direct ownership by 36% to 806,572 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERHead, Strat. & Port. Dev. Pignagnoli Agosti Marcello was granted 27,740 units of American Depositary Shares, increasing direct ownership by 19% to 172,348 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Transformation Officer Duprey Lauren Rusckowski was granted 59,990 units of American Depositary Shares, increasing direct ownership by 36% to 228,503 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERCEO - Elect Kim Julie So-Young was granted 105,416 units of American Depositary Shares, increasing direct ownership by 32% to 430,145 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Data & Tech. Officer Ricci Gabriele was granted 34,994 units of American Depositary Shares, increasing direct ownership by 28% to 159,126 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERChief Financial Officer Furuta Milano was granted 7,800 units of Ordinary Shares, increasing direct ownership by 16% to 57,900 units (SEC Form 4) (withholding obligation)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, OBU Bitetti Teresa Marie was granted 64,988 units of American Depositary Shares, increasing direct ownership by 34% to 258,136 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, IBU Platford Giles Richard was granted 72,124 units of American Depositary Shares, increasing direct ownership by 32% to 297,363 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- ANALYSTTakeda Pharma upgraded by BernsteinBernstein upgraded Takeda Pharma from Mkt Perform to Outperform
- INSIDERSEC Form 3 filed by new insider Greenway Nicola Deidre Petal3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERSEC Form 3 filed by new insider Farajallah Awny Samaan Botros3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ibrahim Ramy Riad Ahmed3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- PRTakeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis CareAbout 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studiesA significantly greater PASI 75 response rate versus placebo was observed as early as week 4Safety profile consistent with Phase 2b studies with no new safety signals identifiedTORONTO, March 31, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) An
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- PRTakeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis CareAbout 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda ((TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that conven
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- INSIDERSEC Form 3 filed by new insider Butel Jean Luc3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERSEC Form 3 filed by Takeda Pharmaceutical Company Limited3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERSEC Form 3 filed by Takeda Pharmaceutical Company Limited3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERSEC Form 3 filed by Takeda Pharmaceutical Company Limited3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
TAK FAQ
7 questionsWhat does Takeda Pharmaceutical Company Limited do?
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD...Where does TAK stock trade?
Takeda Pharmaceutical Company Limited (TAK) is listed on NYSE.What sector and industry is TAK in?
Takeda Pharmaceutical Company Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Takeda Pharmaceutical Company Limited go public?
Takeda Pharmaceutical Company Limited (TAK) completed its IPO in 2018.What are analysts saying about TAK?
Takeda Pharmaceutical Company Limited has had 6 recent analyst actions on file. The most recent action was from Bernstein: Outperform on 2026-04-08. Recent price targets range from $2000.00 to $2400.00.What companies are similar to TAK?
Notable peers in the same industry include AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), AMGN (Amgen Inc.), BMY (Bristol-Myers Squibb Company), SNY (Sanofi). Compare TAK side-by-side with any of them on Quantisnow.How can I track TAK on Quantisnow?
Quantisnow aggregates Takeda Pharmaceutical Company Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TAK to receive live email and push alerts on every new disclosure.